

Dynamics of Chemotherapy Models

Lakshmi N Sridhar*

Chemical Engineering Department, University of Puerto Rico, Mayaguez, PR 00681-9046, USA

Citation: Sridhar LN. Dynamics of Chemotherapy Models. *J Petro Chem Eng* 2025;3(2):79-84.

Received: 19 April, 2025; Accepted: 13 May, 2025; Published: 15 May, 2025

*Corresponding author: Lakshmi N Sridhar, Chemical Engineering Department, University of Puerto Rico, Mayaguez, PR 00681-9046, USA

Copyright: © 2025 Sridhar LN., This is an open-access article published in *J Petro Chem Eng* (JPCE) and distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Chemotherapy is a drug treatment that uses powerful chemicals to kill fast-growing cancer cells. Cancer cells grow and multiply much more quickly than most cells in the body and it is necessary to destroy the cancerous cells to prevent the loss of life. Many different chemotherapy drugs are available. Since cancer cells multiply rapidly, the interaction dynamics between the drugs and the cancer cells need to be understood and controlled. Bifurcation analysis is a powerful mathematical tool used to describe the dynamics of any process. Several factors must be considered and multiple objectives need to be met simultaneously. Bifurcation analysis and multi objective nonlinear model predictive control (MNLMP) calculations were performed on two chemotherapy models. The MATLAB program MATCONT was used to perform the bifurcation analysis. The MNLMP calculations were performed using the optimization language PYOMO in conjunction with the state-of-the-art global optimization solvers IPOPT and BARON. The bifurcation analysis revealed branch points in both models. The branch points were beneficial because they enabled the multi objective nonlinear model predictive control calculations to converge to the Utopia point, which is the best solution.

Keywords: Bifurcation Optimization; Control; Cancer tumor; Chemotherapy

Background

Agur, et al¹. developed mathematical models for cancer immunotherapy. Robertson-Tessi, et al². developed a mathematical model of tumor-immune interactions. Batmani, et al³. determined optimal drug regimens in cancer chemotherapy using a multi-objective approach. Wang, et al⁴, introduced mathematical modeling in cancer drug discovery. Lopez, et al⁵. developed a validated mathematical model of tumor growth including tumor-host interaction, cell-mediated immune response and chemotherapy. Liu, et al⁶. developed a mathematical model of cancer treatment by radiotherapy. Roesch, et al⁷. performed modelling work involving lymphoma therapy. Michor, et al⁸. used mathematical modelling to improve cancer treatment. Robertson-Tessi, et al⁹. developed a model for studying adaptive immunity on tumor response to chemotherapy and chemoimmunotherapy.

Pang, et al¹⁰. developed a mathematical model and analyzed tumor treatment regimens with pulsed immunotherapy and chemotherapy. Feizabadi, et al¹¹. modeled multi-mutation and drug resistance. Heesterman, et al¹². discussed mathematical models for tumor growth and the reduction of overtreatment. Lestari, et al¹³, discussed the dynamics of a mathematical model of cancer cells with Chemotherapy. Akhmetzhanov, et al¹⁴, modeled bistable tumor population dynamics to design effective treatment strategies.

Subramanian, et al¹⁵. studied glioblastoma growth using a 3D multispecies tumor model with mass effect. Shu, et al¹⁶. performed mathematical modeling and bifurcation analysis of pro- and anti-tumor macrophages. Pang, et al¹⁷. performed a dynamic analysis of anti-tumor immune response. Magee, et al¹⁸. compared immunotherapy agents with chemotherapy in solid organ tumors.

Abernathy, et al¹⁹, developed a mathematical model for tumor growth and treatment using virotherapy. Yousef, et al²⁰, performed mathematical modeling of the immune-chemotherapeutic breast cancer treatment under some control parameters. Song, et al²¹, developed a mathematical model of cell-mediated immune response to tumors. Song, et al²², performed mathematical Modeling and Analysis of Tumor Chemotherapy. Bashkirtseva, et al²³, modeled and analyzed tumor-immune interaction under chemotherapy and radiotherapy. Alqahtani, et al²⁴, developed an Effector-cell Interactions under chemotherapy model.

Bifurcation analysis and single-objective optimal control calculations were performed disjointly on chemotherapy problems. This work involves the development of an integrating mathematical framework where Mult objective nonlinear model predictive control calculations (MNLMP) are performed in conjunction with bifurcation analysis on two chemotherapy models described in Song, et al²² and Alqahtani, et al²⁴.

This manuscript is organized as follows: First, the two models are presented, followed by a description of the numerical techniques (Bifurcation analysis and MNLMP). The results, discussion and conclusions are then presented.

Chemotherapy Models

The chemotherapy models are very complex, with considerable differences in values of the variables and parameters involved. Hence, they are often scaled to make them more tractable. Two of the scaled models that will be used for the calculations are described in Song, et al²² and Alqahtani, et al²⁴.

Model 1²²

The scaled model variables are tumor cell population at time t ($tval$), $nval$ (t) the NK cell population, $lval$ (t) for cytotoxic $tval$ cell (CTLs) population and $uval$ (t) the amount of drug at the tumor site. Natural killer cells (NK) are innate lymphocytes endowed with the ability to recognize and kill cancer cells.

$$\begin{aligned}\frac{d(nval)}{dt} &= 10(nval)(1 - 0.018(nval)) - nval(tval + uval) \\ \frac{d(lval)}{dt} &= nval(tval) - lval - (3.42(10^{-03})(lval)tval) - uval(lval); \\ \frac{d(tval)}{dt} &= 25.7(tval(1 - (2.04(10^{-04})tval))) - (nval(tval)) \\ &\quad - 6.02(10^3)(lval)(tval) - 0.4(uval(tval)) \\ \frac{d(uval)}{dt} &= s - 0.1(uval)\end{aligned}$$

s is the ratio of the product of the Immune cell killed and drug Influx of drug divided by the square of the CTL death rate. It is used as the bifurcation parameter and the control variable. More details of this model are in Song, et al²².

Model 2²⁴

The scaled model equations are

$$\begin{aligned}\frac{d(eval)}{dt} &= 0.12 + \frac{(1.13(eval)tval)}{(gval + tval)} \dots \\ &\quad - (mval(eval)tval) - (0.37eval) - (450mval(eval)) \\ \frac{d(tval)}{dt} &= 1.636tval(1 - 0.002tval) - (eval(tval)) - (450mval(tval)) \\ \frac{d(mval)}{dt} &= -(8.18 * mval) + vcont;\end{aligned}$$

The effector cells are represented by $eval$ (predator) and tumor cells by $tval$. The concentration of the chemotherapy drug is denoted $mval$. The amount of drug administered to the body is represented by $vcont$, which is used as the bifurcation parameter and the control variable.

Bifurcation Analysis

The MATLAB software MATCONT is used to perform the bifurcation calculations. Bifurcation analysis deals with multiple steady-states and limit cycles. Multiple steady states occur because of the existence of branch and limit points. Hopf bifurcation points cause limit cycles. A commonly used MATLAB program that locates limit points, branch points and Hopf bifurcation points is MATCONT^{25,26}. This program detects Limit points (LP), branch points (BP) and Hopf bifurcation points(H) for an ODE system

$$\frac{dx}{dt} = f(x, \alpha)$$

$x \in R^n$ Let the bifurcation parameter be α Since the gradient is orthogonal to the tangent vector,

The tangent plane at any point $W = [w_1, w_2, w_3, w_4, \dots, w_{n+1}]$ must satisfy

$$Aw = 0$$

Where A is

$$A = [\partial f / \partial x \quad | \quad \partial f / \partial \alpha]$$

where $\partial f / \partial x$ is the Jacobian matrix.

For both limit and branch points, the matrix $[\partial f / \partial x]$ must be singular. The $n+1$ th component of the tangent vector $W_{n+1} = 0$ for a limit point (LP) and for a branch point (BP) the matrix $\begin{bmatrix} A \\ w^T \end{bmatrix}$ must be singular. At a Hopf bifurcation point,

$$\det(2f_x(x, \alpha) @ I_n) = 0$$

@ indicates the bialternate product while I_n is the n -square identity matrix. Hopf bifurcations cause limit cycles and should be eliminated because limit cycles make optimization and control tasks very difficult. More details can be found in Kuznetsov^{27,28} and Govaerts²⁹.

Mult objective nonlinear model predictive control

Flores Tlacuahuaz, et al³⁰, developed a Mult objective nonlinear model predictive control (MNLMP) method that is rigorous and does not involve weighting functions or additional constraints. This procedure is used for performing the MNLMP calculations.

Here $\sum_{t_i=0}^{t_f=t_f} q_j(t_i)$ ($j=1,2, \dots, n$) represents the variables that need to be minimized/maximized simultaneously for a problem involving a set of ODES

$$\frac{dx}{dt} = F(x, u)$$

t_f being the final time value and n the total number of objective variables and u the control parameter. This MNLMPC procedure first solves the single objective optimal control problem independently optimizing each of the variables

$\sum_{t_i=0}^{t_i=t_f} q_j(t_i)$ individually. The minimization/maximization of $\sum_{t_i=0}^{t_i=t_f} q_j(t_i)$ will lead to the values q_j^* . Then the optimization problem that will be solved is

$$\min \left(\sum_{j=1}^n \left(\sum_{t_i=0}^{t_i=t_f} q_j(t_i) - q_j^* \right)^2 \right)$$

$$\text{subject to } \frac{dx}{dt} = F(x, u);$$

This will provide the values of u at various times. The first obtained control value of u is implemented and the rest are discarded. This procedure is repeated until the implemented and the first obtained control values are the same or if the Utopia

point where $\left(\sum_{t_i=0}^{t_i=t_f} q_j(t_i) = q_j^* \right)$ for all j is obtained.

Pyomo³¹, is used for these calculations. Here, the differential equations are converted to a Nonlinear Program (NLP) using the orthogonal collocation method. The NLP is solved using IPOPT³² and confirmed as a global solution with BARON³³.

The steps of the algorithm are as follows

Optimize $\sum_{t_i=0}^{t_i=t_f} q_j(t_i)$ and obtain q_j^* at various time intervals t_i . The subscript i is the index for each time step.

Minimize $\left(\sum_{j=1}^n \left(\sum_{t_i=0}^{t_i=t_f} q_j(t_i) - q_j^* \right)^2 \right)$ and get the control values for various times.

Implement the first obtained control values

Repeat steps 1 to 3 until there is an insignificant difference between the implemented and the first obtained value of the control variables or if the Utopia point is achieved. The Utopia

point is when $\sum_{t_i=0}^{t_i=t_f} q_j(t_i) = q_j^*$ for all j .

Sridhar³⁴, proved that the MNLMPC calculations to converge to the Utopia solution when the bifurcation analysis revealed the presence of limit and branch points. This was done by imposing the singularity condition on the co-state equation³⁵. If the minimization of q_1 lead to the value q_1^* and the minimization of q_2 lead to the value q_2^* . The MNLMPC calculations will minimize the function $(q_1 - q_1^*)^2 + (q_2 - q_2^*)^2$. The Mult objective optimal control problem is

$$\min (q_1 - q_1^*)^2 + (q_2 - q_2^*)^2 \quad \text{subject to } \frac{dx}{dt} = F(x, u)$$

Differentiating the objective function results in

$$\frac{d}{dx_i} ((q_1 - q_1^*)^2 + (q_2 - q_2^*)^2) = 2(q_1 - q_1^*) \frac{d}{dx_i} (q_1 - q_1^*) + 2(q_2 - q_2^*) \frac{d}{dx_i} (q_2 - q_2^*)$$

The Utopia point requires that both $(q_1 - q_1^*)$ and $(q_2 - q_2^*)$ are zero. Hence

$$\frac{d}{dx_i} ((q_1 - q_1^*)^2 + (q_2 - q_2^*)^2) = 0$$

the optimal control co-state equation (Upreti; 2013) is

$$\frac{d}{dt}(\lambda_i) = -\frac{d}{dx_i} ((q_1 - q_1^*)^2 + (q_2 - q_2^*)^2) - f_x \lambda_i; \quad \lambda_i(t_f) = 0$$

λ_i is the Lagrangian multiplier. t_f is the final time. The first term in this equation is 0 and hence

$$\frac{d}{dt}(\lambda_i) = -f_x \lambda_i; \quad \lambda_i(t_f) = 0$$

At a limit or a branch point, for the set of ODE $\frac{dx}{dt} = f(x, u)$ f_x is singular. Hence there are two different vectors-values for

$[\lambda_i]$ where $\frac{d}{dt}(\lambda_i) > 0$ and $\frac{d}{dt}(\lambda_i) < 0$. In between there

is a vector $[\lambda_i]$ where $\frac{d}{dt}(\lambda_i) = 0$. This coupled with the

boundary condition $\lambda_i(t_f) = 0$ will lead to $[\lambda_i] = 0$. This makes the problem an unconstrained optimization problem and the only solution is the Utopia solution.

Hopf bifurcations cause unwanted oscillatory behavior and limit cycles. The tanh activation function (where a control value u is replaced by $(u \tanh u / \varepsilon)$) is commonly used in neural nets³⁶⁻³⁸ and optimal control problems³⁹ to eliminate spikes in the optimal control profile. Hopf bifurcation points cause oscillatory behavior. Oscillations are similar to spikes and the results in Sridhar(2024b) demonstrate that the tanh factor also eliminates the Hopf bifurcation by preventing the occurrence of oscillations. Sridhar⁴⁰, explained with several examples how the activation factor involving the tanh function successfully eliminates the limit cycle causing Hopf bifurcation points. This was because the tanh function increases the time period of the oscillatory behavior, which occurs in the form of a limit cycle caused by Hopf bifurcations.

Results and Discussion

The bifurcation analysis performed with MATCONT on model 1 revealed a branch point at $(nval, lval, tval, uval, s) = (0, 0, 0, 10, 1)$. The bifurcation parameter is s . This branch point BP resulted in 2 solution branches as shown in (Figure 1).




Figure 1: Bifurcation Diagram (Model 1).

For the MNLMPCC calculation, with s is the control variable, $\sum_{t_i=0}^{t_i=t_f} tval_j(t_i)$ was minimized, leading to a value of 0 and $\sum_{t_i=0}^{t_i=t_f} nval_j(t_i)$ was maximized resulting in a value of 20. The overall optimal control problem will involve the minimization

$$\text{of } \left(\sum_{t_i=0}^{t_i=t_f} tval_j(t_i) - 0 \right)^2 + \left(\sum_{t_i=0}^{t_i=t_f} nval_j(t_i) - 20 \right)^2 \text{ subject to}$$

the ODE describing Model 1. This minimization resulted in the Utopia point (0) confirming the analysis of Sridhar³⁴, which showed that the presence of a branch point enables the MNLMPCC calculations to reach the best possible (Utopia) solution. The first of the control variable is implemented and the rest are discarded. The process is repeated until the difference between the first and second values of the control variables are the same. This MNLMPCC control value was 0.8409. The various MNLMPCC profiles are shown in (Figure 2). The obtained control profile of s exhibited a lot of noise (Figure 3). This was remedied using the Savitzky-Golay Filter. The smoothed-out version of this profile is shown in (Figure 4).




Figure 2: eval, nval, tval (MNLMPCC model 1).




Figure 3: s profile (MNLMPCC model 1).




Figure 4: s profile with Savitsky Golay filter MNLMPCC model 1).

In model 2, a branch point was obtained at $(eval, tval, mval, vcont) = (0.061719, 0.0, 0.003498, 0.028617)$. This is shown in (Figure 5).




Figure 5: Bifurcation Diagram (Model 2).

For the MNLMPCC calculation, using $vcont$ is the control variable, $\sum_{t_i=0}^{t_i=t_f} tval_j(t_i)$ and $\sum_{t_i=0}^{t_i=t_f} eval_j(t_i)$ are both minimized, each leading to a value of 0. The overall optimal control problem will involve the minimization of $\left(\sum_{t_i=0}^{t_i=t_f} tval_j(t_i) - 0 \right)^2 + \left(\sum_{t_i=0}^{t_i=t_f} eval_j(t_i) - 0 \right)^2$ subject to the ODE describing Model 2. This minimization resulted in the Utopia point (0) confirming the analysis of Sridhar³⁴, which showed that the presence of a branch point enables the MNLMPCC calculations to reach the best possible (Utopia) solution. The first of the control variable is implemented and the rest are discarded. The process is repeated until the difference between the first and second values of the control variables are the same. This MNLMPCC control value was .2385. The various MNLMPCC profiles are shown in (Figure 6). The obtained control profile of s exhibited noise (Figure 7). This was remedied using the Savitzky-Golay Filter. The smoothed-out version of this profile is shown in (Figure 8). Although one of the branches is in an infeasible region (Figure 2) the branch point in the feasible region indicates a singularity of the Jacobian matrix. This singularity causes the MNLMPCC calculations to converge to the Utopia point.




Figure 6: eval, mval, tval profiles MNLMPCC model 2).




Figure 7: vcont profile MNLMP model 2)




Figure 8: vcont profile with Savitsky Golay filter MNLMP model 2).

Conclusion

Mult objective nonlinear model predictive control calculations were performed along with bifurcation analysis on scaled chemotherapy models. The bifurcation analysis revealed the existence of brach points that produced different solution branches originating from a singular point. The presence of a branch point is very beneficial as it caused the Mult objective nonlinear model predictive calculations to converge to the Utopia point, which is the best possible solution.

Data Availability Statement

All data used is presented in the paper.

Conflict of interest

The author, Dr. Lakshmi N Sridhar has no conflict of interest.

Acknowledgement

Dr. Sridhar thanks Dr. Carlos Ramirez and Dr. Suleiman for encouraging him to write single-author papers.

References

- Agur Z, Vuk-Pavlovic S. Mathematical modeling in immunotherapy of cancer: Personalizing clinical trials. *Mol Ther* 2012;20:1-2.
- Robertson-Tessi M, El-Kareh A, Goriely A. A mathematical model of tumor-immune interactions. *J Theor Biol* 2012;294:56-73.
- Batmani Y, Khaloozadeh H. Optimal drug regimens in cancer chemotherapy: A multi-objective approach. *Comput Biol Med* 2013;43:2089-2095.
- Wang Z, Deisboeck TS. Mathematical modeling in cancer drug discovery. *Drug Discov Today* 2014;19:145-150.
- Lopez AG, Seoane JM, Sanjuan MA. A validated mathematical model of tumor growth including tumor-host interaction, cell-mediated immune response and chemotherapy. *Bull Math Biol* 2014;76:2884-2906.
- Liu Z, Yang C. A mathematical model of cancer treatment by radiotherapy. *Math Comput Simulat* 2014;7:172923.
- Roesch K, Hasenclever D, Scholz M. Modelling Lymphoma Therapy and Outcome. *Bull Math Biol* 2014;76:401-430.
- Michor F, Beal K. Improving cancer treatment via mathematical modeling: Surmounting the challenges is worth the effort. *Cell* 2015;163:1059-1063.
- Robertson-Tessi M, El-Kareh A, Goriely A. A model for effects of adaptive immunity on tumor response to chemotherapy and chemoimmunotherapy. *J Theor Biol* 2015;380:569-584.
- Pang L, Lin S, Zhong Z. Mathematical modelling and analysis of the tumor treatment regimens with pulsed immunotherapy and chemotherapy. *Comput Math Methods Med* 2016;2016:6260474.
- Feizabadi MS. Modeling multi-mutation and drug resistance: Analysis of some case studies. *Theor Biol Med Model* 2017;14:275-289.
- Heesterman BL, Bokhorst JM, de Pont LM, et al. Mathematical models for tumor growth and the reduction of overtreatment. *J Neurol Surg B Skull Base* 2019;80:72-78.
- Lestari D, Sari ER, Arifah H. Dynamics of a mathematical model of cancer cells with Chemotherapy. *J Phys Conf Ser* 2019;1320:012026.
- Akhmetzhanov AR, Kim JW, Sullivan R, Beckman RA, Tamayo P, Yeang CH. Modelling bistable tumour population dynamics to design effective treatment strategies. *J Theor Biol* 2019;474:88-102.
- Subramanian S, Gholami A, Biros G. Simulation of glioblastoma growth using a 3D multispecies tumor model with mass effect. *J Math Biol* 2019;79:941-967.
- Shu Y, Huang J, Dong Y, Takeuchi Y. Mathematical modeling and bifurcation analysis of pro- and anti-tumor macrophages. *Appl Math Mol* 2020;88:758-733.
- Pang L, Liu S, Zhang X, Tian T. Mathematical modeling and dynamic analysis of anti-tumor immune response. *J Appl Math Comput* 2020;62:473-488.
- Magee DE, Hird AE, Klaassen Z, Sridhar SS, Nam RK, Wallis CJD, Kulkarni GS. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: A systematic review and meta-analysis of randomized clinical trials. *Ann Oncol* 2020;31:50-60.
- Abernathy Z, Abernathy K, Stevens J. A mathematical model for tumor growth and treatment using virotherapy. *AIMS Math* 2020;5:4136-4150.
- Yousef A, Bozkurt F, Abdeljawad T. Mathematical modeling of the immune-chemotherapeutic treatment of breast cancer under some control parameters. *Adv Differ Equ* 2020;2020:696.
- Song G, Tian T, Zhang X. A mathematical model of cell-mediated immune response to tumor. *Math Biosci Eng* 2020;18:373.
- Song G, Liang G, Tian T, Zhang X. Mathematical Modeling and Analysis of Tumor Chemotherapy. *Symmetry* 2022;14:704.
- Bashkirtseva I, Chukhareva A, Ryashko L. Modeling and analysis of nonlinear tumor-immune interaction under chemotherapy and radiotherapy. *Math Methods Appl Sci* 2022;45:7983-7991.
- Alqahtani RT. A Model of Effector-Tumor Cell Interactions Under Chemotherapy: Bifurcation Analysis. *Mathematics* 2025;13:1032.
- Dhooge A, Govaerts W, Kuznetsov AY. MATCONT: A Matlab package for numerical bifurcation analysis of ODEs. *ACM transactions on Mathematical software* 2003;29(2):141-164.

26. Govaerts W, Kuznetsov YA, De Witte V. CL_MATCONT. A continuation toolbox in Matlab 2004.
27. Kuznetsov YA. Elements of applied bifurcation theory. Springer NY 1998.
28. Kuznetsov YA. Five lectures on numerical bifurcation analysis. Utrecht University, NL 2009.
29. Govaerts WJF. Numerical Methods for Bifurcations of Dynamical Equilibria. SIAM 2000.
30. Flores-Tlacuahuac A. Pilar Morales and Martin Rival Toledo; Multi objective Nonlinear model predictive control of a class of chemical reactors. I & EC research 2012;5891-5899.
31. William EH, Laird CD, Watson JP, et al. Sirola. Pyomo - Optimization Modeling. Python Second Edition 67.
32. Wächter A, Biegler L. On the implementation of an interior-point filter line-search algorithm for large-scale nonlinear programming. Math Program 2006;106:25-57.
33. Tawarmalani M, Sahinidis NV. A polyhedral branch-and-cut approach to global optimization. Mathematical Programming 2005;103(2):225-249.
34. Sridhar LN. Coupling Bifurcation Analysis and Multiobjective Nonlinear Model Predictive Control. Austin Chem Eng 2024;10(3):1107.
35. Ranjan US. Optimal control for chemical engineers. Taylor and Francis 2013.
36. Dubey SR, Singh SK, Chaudhuri BB. Activation functions in deep learning: A comprehensive survey and benchmark. Neurocomputing 2022;503:92-108.
37. Kamalov A. F. Nazir M. Safaraliev, Cherukuri AK, Zgheib R. Comparative analysis of activation functions in neural network. 2021 28th IEEE International Conference on Electronics, Circuits, Systems (ICECS), Dubai, United Arab Emirates 2021:1-6.
38. Szandala T. Review and Comparison of Commonly Used Activation Functions for Deep Neural Networks 2020.
39. Sridhar LN. Bifurcation Analysis and Optimal Control of the Tumor Macrophage Interactions. Biomed J Sci Tech Res 2023;53(5).
40. Sridhar LN. Elimination of oscillation causing Hopf bifurcations in engineering problems. J Applied Math 2024;2(4):1826.